NCT05343377

A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Prospective, Multicenter Clinical Study of Accurate Stratification and Prognostic Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-up was terminated in 4 years. To observe the accuracy of circulating free methylated EBV DNA in predicting 2-year PFS rate, 2-year OS rate, and CR rate in newly diagnosed ENKTCL patients; and to clarify the prognostic stratification ability of PINK-cpgE compared with PINK-E

Conditions

• Extranodal Natural Killer/T-cell Lymphoma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	circulate free methylated EBV DNA	Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS

Timeline

• Start date: 2022-06-01
• Primary completion: 2025-06-01
• Completion: 2028-06-01
• First posted: 2022-04-25
• Last updated: 2022-04-25

Locations

1 site across 1 country: China